Mark A. Munger, Pharm.D., F.C.C.P., F.A.C.C., F.H.F.S.A., HF-Cert., is a distinguished pharmacologist specializing in cardiovascular therapeutics. He is a Professor of Pharmacotherapy at the University of Utah, with extensive experience in clinical pharmacology, education, and health policy. Dr. Munger has served on numerous advisory boards, contributed to health policy initiatives, and played a key role in pharmacy education. His work spans research, teaching, and leadership roles, shaping advancements in cardiovascular pharmacotherapy. He is widely recognized for his contributions to healthcare, education, and clinical practice.
Profile
Education 🎓
Dr. Munger earned his Doctor of Pharmacy (1986) from the University of Illinois, a Bachelor of Science in Pharmacy (1983) from Oregon State University, and completed a Cardiovascular Pharmacology Research Fellowship (1986-87) at Case Western Reserve University and University Hospitals of Cleveland. His academic journey laid the foundation for his impactful career in cardiovascular research, clinical pharmacology, and pharmacy education.
Experience 👨🏫
Dr. Munger has held numerous leadership roles, including Associate Dean at the University of Utah College of Pharmacy (2003-2023), Director of Clinical Pharmacology at UTAH Heart Failure Prevention Program (2000-2012), and Chairperson of the Utah State Board of Pharmacy (2002-2004). His expertise has influenced health policies, clinical research, and pharmacy education. He has also served as a consultant and advisory board member for various healthcare and government organizations.
Research Interests 🔬
Dr. Munger’s research centers on cardiovascular pharmacotherapy, heart failure management, and drug safety. His work has contributed to advancements in pharmacological treatments for cardiovascular diseases, optimizing drug therapy for heart failure patients, and policy-making in healthcare. His studies integrate clinical trials, translational research, and healthcare innovations, enhancing patient outcomes and shaping pharmaceutical practices.
Dr. Munger has received numerous accolades, including Fellowships from the American College of Cardiology (2008), Heart Failure Society of America (2016), and American College of Clinical Pharmacy (1996). He was named University of Illinois College of Pharmacy Alumni of the Year (2008), earned multiple Teacher of the Year nominations, and received the Utah Society of Health-System Pharmacists Leadership Award (2009). His contributions to research and education have been recognized globally.
Publications 📚
-
Association of atrial fibrillation with lamotrigine: An observational cohort study
Pharmacotherapy: The Journal of Human
Pharmacology and Drug Therapy
2025-01 | Journal article
DOI: 10.1002/phar.4633
CONTRIBUTORS: Sodam Kim; Landon Welch; Bertha De Los Santos; Przemysław B. Radwański; Mark A. Munger; Kibum Kim
-
Riluzole is associated with reduced risk of heart failure
2025-01 | Journal article
DOI: 10.1111/ene.70033
CONTRIBUTORS: Kibum Kim; Sodam Kim; Margaret Katana; Dmitry Terentyev; Przemysław B. Radwański; Mark A. Munger
-
Ivabradine and Atrial Fibrillation Incidence: A Nested Matching Study
2025-01-12 | Preprint
DOI: 10.1101/2025.01.10.25320367
CONTRIBUTORS: Kibum Kim; Jasmeen Keur; Halie Anderson; Przemysław B. Radwański; Mark A. Munger
-
Association of Ventricular Arrhythmias with Lamotrigine: An Observational Cohort Study
2024-09-24 | Preprint
DOI: 10.1101/2024.09.10.24313446
CONTRIBUTORS: Sodam Kim; Landon Welch; Bertha De Los Santos; Przemysław B. Radwański; Mark A. Munger; Kibum Kim